Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Anosys is a privately-held biotechnology company which develops and tests medicines to treat cancer, infectious and autoimmune diseases. The company's approach to immunotherapy is based on the discovery of a fundamental mechanism of immunity that facilitates each patient's own natural defence against disease. This approach features the administration of dendritic-derived exosomes, well-characterised, naturally-derived vesicles that contain all the components necessary to activate the major immune responses.

Anosys has successfully developed a technology that can target proteins to the surface of exosomes in an active biological conformation. These exosomes are highly immunogenic, facilitating the production of MAbs to treat different diseases or for use in drug screening. In addition, exosomes can express proteins that would otherwise be difficult to produce with alternate technologies.